Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class (AGIO)
· seekingalpha.com
Agios Pharmaceuticals, Inc. a Sell amid tebapivat setback & tougher PK activator competition; see risks, SCD catalysts, and cash runway. Click for an AGIO update.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...